Miranda, Sergimar PTraiman, Paulo [UNESP]Cândido, Eduardo BLages, Elisa LFreitas, Gustavo FLamaita, Rívia MaraVidigal, Paula V TSilva Filho, Agnaldo Lopes da [UNESP]2014-05-272014-05-272010-12-01International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, v. 20, n. 9, p. 1525-1530, 2010.1525-1438http://hdl.handle.net/11449/72178This study was undertaken to investigate the expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen (TAM). Postmenopausal women with endometrial polyps treated with TAM (n = 20), postmenopausal women with endometrial polyps without hormone use (n = 20), postmenopausal women with atrophic endometrium (n = 20), and postmenopausal women with endometrial adenocarcinoma (n = 20) were prospectively investigated. Tissue samples were immunohistochemically evaluated by monoclonal antibodies for p53, Ki-67, and CD31. The data were analyzed using the Student t test, analysis of variance, and χ2 to evaluate significant differences between the groups. The level of significance was set at P < 0.05. There was no difference in the expression of p53 between the groups (P = 0.067). The expression of Ki-67 was higher in the polyp samples from TAM-treated women compared with those from the women using no hormone (P = 0.0047) and those from the women with atrophic endometrium (P = 0.008). Samples from the women with endometrial cancer was associated with higher Ki-67 expression compared with the polyp samples from TAM-treated women (P = 0.004). The expression of CD31 was higher in the polyp samples of TAM-treated women compared with that of the samples from the women with atrophic endometrium (P < 0.001) and similar to the polyp samples from the women using no hormone (P = 0.319) and to the samples from the women with endometrial cancer (P = 0.418). The use of TAM in postmenopausal women might be associated with increased cellular proliferation in endometrial polyps without interfering angiogenesis or inactivation of tumor suppressor proteins.1525-1530engantineoplastic hormone agonists and antagonistsCD31 antigenKi 67 antigenpharmacological biomarkerprotein p53tamoxifentumor markertumor proteinadenocarcinomaageddrug effectendometriumendometrium tumorevaluationfemalehumanmetabolismmiddle agedpathologypolyppostmenopauseprognosisAdenocarcinomaAgedAged, 80 and overAntigens, CD31Antineoplastic Agents, HormonalBiomarkers, PharmacologicalEndometrial NeoplasmsEndometriumFemaleHumansKi-67 AntigenMiddle AgedNeoplasm ProteinsPolypsPostmenopausePrognosisTamoxifenTumor Markers, BiologicalTumor Suppressor Protein p53ArtigoWOS:000284822900014Acesso restrito2-s2.0-799577981198334785337106990